<DOC>
	<DOCNO>NCT02160041</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment BGJ398 demonstrate sufficient efficacy select FGFR pathway-regulated solid tumor and/or hematologic malignancy warrant study .</brief_summary>
	<brief_title>BGJ398 Patients With Tumors With FGFR Genetic Alterations</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patient confirm diagnosis select solid tumor ( except primary diagnosis Urothelial cell carcinoma , Cholangiocarcinoma , Endometrial cancer , Glioblastoma multiforme ) hematologic malignancy need treatment progression relapse . Patient 's tumor evaluate preidentified tumor FGFR genetic alteration . The qualify alteration must assess report CLIAcertified laboratory . Patient must receive least one prior treatment recurrent , metastatic /or locally advance disease standard therapy option anticipate result durable remission . Patient must progressive measurable disease per RECIST 1.1. appropriate hematological response criterion . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patient receive prior treatment BGJ398 Patients Central Nervous System ( CNS ) metastasis leptomeningeal carcinomatosis Patient receive chemotherapy anticancer therapy ≤ 4 week ( 6 week nitrosourea , antibody mitomycinC ) prior start study drug . Patients acute chronic pancreatitis Patients impaired cardiac function clinically significant cardiac disease History and/or current evidence extensive tissue calcification Use medication increase serum level phosphorus and/or calcium Current evidence corneal retinal disorder/keratopathy History and/or current evidence renal endocrine alteration calcium/phosphate homeostasis Patients another primary malignancy within 3 year prior start study treatment , exception adequately treat basal cell carcinoma , squamous cell carcinoma nonmelanomatous skin cancer , insitu carcinoma uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid tumor malignancy</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>mutation</keyword>
	<keyword>translocation</keyword>
	<keyword>amplification ,</keyword>
	<keyword>fusion</keyword>
	<keyword>signature</keyword>
	<keyword>FGFR</keyword>
	<keyword>ligand</keyword>
	<keyword>BGJ398</keyword>
</DOC>